Latest News

BioSim Pharmaceuticals to Meet with Industry at 2017 BIO Investor Forum in San Francisco.

Seattle, Wash. � Oct. 5 2017,
BioSim Pharmaceuticals, LLC., a biopharmaceutical company focused on the development of biological generic injectables, announced today that they will be at the 15th Annual BIO Investor Forum.

Held in San Francisco, the BIO Investor Forum, is a world-renowned investment conference in the healthcare industry. BioSim Pharmaceuticals will be taking advantage of the conference period to meet with the investment community and partners to share groundbreaking news of the successful milestones achieved in their research and development program.

After three years of R&D, BioSim’s flagship product, an ACTH Gel, looks to become the first generic to capture this billion dollar market. From there, the company plans to maintain market share by pricing its interchangeable products significantly well below half of potential ACTH competitors. The ACTH 16% gel is a generic version of the branded drug H.P. ACTHAR®, manufactured by Mallinckrodt Plc (NYSE: MNK). Last year, Mallinckrodt acquired the previous owner, Questcor Pharmaceuticals, for $5.6 billion. ACTHAR, priced at over $30,0000 per vial, is a biologic drug also known as Corticotropin. Among its several indications, the drug treats infantile spasms, rare autoimmune disorders such as nephrotic syndrome, and multiple sclerosis and currently is in clinical trials for ALS (Amyotrophic Lateral Sclerosis).

In recent years, the market for specialty biopharmaceutical products for rare orphan diseases has blossomed. For established companies like Baxter International and Momenta Pharmaceuticals, the space continues to see rapid growth. BioSim has positioned itself to be a low-cost generic leader in the niche orphan drug market with the goal of helping lower the cost of medicine for America’s Healthcare System. Recently, prescription drug costs have been increased by companies like Turing Pharmaceuticals and in turn, Hillary Clinton also addressed the need for change.

Parties interested in securing a meeting with BioSim, contact

About BioSim Pharmaceuticals
BioSim (, a Seattle-based pharmaceutical company started in early 2012, is focused on building a portfolio around complex generic drugs for the orphan disease and biologic marketplace. BioSim consists of a team of highly capable individuals with decades of pharmaceutical experience all working together to bring products to market that help lower the escalating cost of healthcare. * * *

H.P. ACTHAR� is a registered trademark of their respective owner.